A closely watched treatment for Alzheimer's disease came up short in a late-stage trial, marking the latest setback in a field wracked by years of failure.
The drug, from biotech company TauRx, did no better than a sugar pill at improving patients' scores on tests of cognitive and physical function, according to data presented early Wednesday at the Alzheimer's Association International Conference in Toronto. The study looked at roughly 900 patients with mild to moderate forms of Alzheimer's.
“I must say I'm disappointed by the results,” said Dr. David Knopman, a Mayo Clinic neurologist not involved with the study.
Read Full Article »